A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)

Phase 1

Terminated

• Conditions: Rotavirus

• Registration Number: NCT00836498
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

This is a Phase I clinical trial including 2 parts to evaluate the safety and immune response to RotaTeq™ /placebo in subjects of 65 to 80 years of age. In Part I, approximately 60 subjects in US will be randomly assigned to 1 of 2 treatment groups receiving 3 doses of RotaTeq™ or placebo. In Part II, approximately 200 subjects internationally will be randomly assigned to 1 of 3 treatment groups. Part II will start after Part I data analysis is reviewed and approved by the FDA/CBER, the Safety Evaluation Committee (SEC) and other regulatory agencies. Duration for the entire study will be approximately 4 years.

Note: As the result of a business decision by the Sponsor, the study did not proceed with Part II. Therefore, this report includes the results for Part I only.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-01
• Study First Submitted: 2009-02-03
• Study First Submitted QC: 2009-02-03
• Study First Posted: 2009-02-04
• Primary Completion: 2010-01
• Study Completion: 2010-01
• Results First Submitted: 2011-01-12
• Results First Submitted QC: 2011-01-12
• Results First Posted: 2011-02-04
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-10
• Last Update Posted: 2015-05-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• Is 65 to 80 years of age with controlled chronic illness
• agrees to participate in the study by giving written informed consent and cognitively competent as assessed by Mini-Mental State Examination
• for Part I: subject is living independently outside any long-term care facilities; for Part II: subject is expected to be a resident in a long term care facility (LTCF) including nursing homes with the exception of hospice care
• can be adequately followed for safety via visit or phone
• subject's routine safety lab results are within specified ranges
• has negative test results for HIV, Hepatitis B, and Hepatitis C

Read More

Exclusion Criteria

• abdominal cancer/surgery within the past 6 months
• known or suspected immune diseases, e.g. diabetes
• any chronic or relapsing infections
• a fever at the time of immunization
• active vomiting or diarrhea at the time of immunization
• chronic diarrhea, irritable bowel syndrome, or inflammatory disease of intestinal or colon in the past 12 months
• subjects' spouses/cohabitants are not healthy or are immunocompromised; roommates in LTCFs are not healthy and/or do not agree to participate in the study
• cannot be adequately followed for safety via visit or phone
• any other clinically significant conditions that, in the investigators' opinion, would interfere with subject's participation in the study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Part I: Number of Participants With Nonserious and Serious Adverse Experiences (AEs)	Up to 42 days following any dose of RotaTeq™ or placebo	All randomized participants were contacted via telephone or in-center visit on Days 7, 14, 28, and 42 after each dose. Participants received a Vaccination Report Card (VRC) at each vaccination visit as well as instructions for recording AEs. Participants were also instructed to record potential acute gastroenteritis episodes (AGEs) that occurred within 42 days after any dose on the report card.
Part I: Number of Participants With Serious Adverse Experiences (SAEs)	Up to 180 days following the third dose of RotaTeq™ or placebo	All randomized participants were contacted via telephone or in-center visit on Days 7, 14, 28, and 42 after each dose. Participants received a Vaccination Report Card (VRC) at each vaccination visit as well as instructions for recording AEs. Participants were also instructed to record potential acute gastroenteritis episodes (AGEs) that occurred within 42 days after any dose on the report card.; SAEs were followed by passive surveillance (in which either participants self reported or information was collected at participants' last visit) for 180 days following the final dose.
Part I: Geometric Mean Titers (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)	Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo	GMTs of serum anti-rotavirus IgA responses after 1, 2, or 3 doses of RotaTeq™ or placebo.
Part II: Number of Participants With Nonserious Adverse Experiences	Up to 42 days following any dose of RotaTeq™ and/or placebo	Part II was not conducted due to study termination; this report summarizes study results from Part I only.
Part II: Number of Participants With Serious Adverse Experiences	Up to 180 days following the third dose of RotaTeq™ and/or placebo	Part II was not conducted due to study termination; this report summarizes study results from Part I only.
Part II: Geometric Mean Titer (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)	Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3	Part II was not conducted due to study termination; this report summarizes study results from Part I only.

Secondary Outcome Measures

Name	Time	Method
Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G1	Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo
Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G2	Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo
Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G3	Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo
Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G4	Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo
Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype P1A[8]	Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo
Part II: Geometric Mean Titers (GMTs) of Serum Neutralizing Antibody (SNA) Responses to G1, G2, G3, G4, and P1A	Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3	Part II was not conducted due to study termination; this report summarizes study results from Part I only.
Part II: Percentage of Participants With a >=3-fold Rise From Baseline of Serum Anti-rotavirus IgA and SNA Responses to Rotavirus Serotypes G1, G2, G3, G4 and P1A	Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3	Part II was not conducted due to study termination; this report summarizes study results from Part I only.